About
Mary Thistle has served on Aktis Oncology's board of directors since January 2025. She previously served as Special Advisor and earlier Chief of Staff at the Bill & Melinda Gates Medical Research Institute, and held senior leadership positions including Chief Operating Officer at Dimension Therapeutics and business development leadership roles at Cubist Pharmaceuticals. She currently serves on the boards of Cullinan Therapeutics, Q32 Bio, Entrada Therapeutics and Vigil Neuroscience.
Roles
Aktis Oncology, Inc.
Director · Current role
January 2025–present
Bill & Melinda Gates Medical Research Institute
Special Advisor; earlier Chief of Staff
January 2018 - June 2022
Dimension Therapeutics, Inc.
Chief Operating Officer; earlier Chief Business Officer
2015 - 2017
Cubist Pharmaceuticals, Inc.
Senior Vice President, Business Development
2009 - 2015
External Roles
Cullinan Therapeutics, Inc.
Director
August 2024 - present
Q32 Bio Inc.
Director
March 2024 - present
Entrada Therapeutics, Inc.
Director
May 2021 - present
Vigil Neuroscience, Inc.
Director
April 2022 - present
Also at Aktis Oncology, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.